RxDoctor Payments Data

Bethany Territo

Family · Liverpool, NYNPI 1356008791

Payments from drug & device makers

$3,868in general payments, 2019–2025

Across 127 payments — averaging $30.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$776
  • Medtronic$342
  • Collegium Pharmaceutical, Inc.$241
  • Biohaven Pharmaceutical Holding Company Ltd.$185
  • Nevro Corp.$183
  • plus $804 from 14 others

What the payments were for

  • Travel & lodging$2687%
  • Food & beverage$3,59993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,868 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$68,090
Medicare patients
57
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$35,958
Nurtec OdtRimegepant Sulfate19$20,399
TrulicityDulaglutide20$19,681
JardianceEmpagliflozin25$7,757
MovantikNaloxegol Oxalate15$4,845
Sevelamer Carbonate14$3,741
Gabapentin144$3,706
GemtesaVibegron14$3,418
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc27$2,392
Fiasp FlextouchInsulin Aspart (Niacinamide)11$2,160
Paliperidone ErPaliperidone11$1,929
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$1,830
Celecoxib47$1,717
Atorvastatin Calcium94$1,636
Pregabalin34$1,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$154$56,357137 claims
Lilly USA, LLCTrulicity$178$19,68120 claims
Almatica Pharma LLCSertraline Hcl$39$66542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →